Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 February 2019Website:
http://www.gossamerbio.comNext earnings report:
05 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Sat, 23 Nov 2024 00:54:49 GMTDividend
Analysts recommendations
Institutional Ownership
GOSS Latest News
Gossamer Bio (GOSS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Gossamer Bio (GOSS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
The heavy selling pressure might have exhausted for Gossamer Bio (GOSS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Gossamer Bio (GOSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.21 per share a year ago.
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.
Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Gossamer Bio announced a partnership with Chiesi Group to develop and market its drug seralutinib for various conditions related to blood pressure.
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
What type of business is Gossamer Bio?
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The company was registered in the state of Delaware on October 25, 2015, and is based in San Diego, California. They have 4 product candidates in clinical stage and several preclinical programs: GB001 (DP2 antagonist) - for the treatment of eosinophilic asthma and other allergic reactions. GB002 (PDGF receptor kinase inhibitor) - for the treatment of pulmonary arterial hypertension. GB004 (HIF-1 α stabilizer) - for the treatment of inflammatory bowel disease, including ulcerative colitis, Crohn's disease. GB1275 (CD11b modulator) - for the treatment of oncological diseases. None of their developed drugs have reached the commercial stage. All are in various stages of preclinical development.
What sector is Gossamer Bio in?
Gossamer Bio is in the Healthcare sector
What industry is Gossamer Bio in?
Gossamer Bio is in the Biotechnology industry
What country is Gossamer Bio from?
Gossamer Bio is headquartered in United States
When did Gossamer Bio go public?
Gossamer Bio initial public offering (IPO) was on 08 February 2019
What is Gossamer Bio website?
https://www.gossamerbio.com
Is Gossamer Bio in the S&P 500?
No, Gossamer Bio is not included in the S&P 500 index
Is Gossamer Bio in the NASDAQ 100?
No, Gossamer Bio is not included in the NASDAQ 100 index
Is Gossamer Bio in the Dow Jones?
No, Gossamer Bio is not included in the Dow Jones index
When was Gossamer Bio the previous earnings report?
No data
When does Gossamer Bio earnings report?
The next expected earnings date for Gossamer Bio is 05 March 2025